Tissue schizontocidal effect of trifluoroacetyl primaquine in Plasmodium yoelii infected mice and Plasmodium cynomolgi infected monkeys.
Trifluoroacetyl primaquine oxalate (M8506) was compared with primaquine phosphate for tissue schizontocidal action in rodent and simian malaria. In Plasmodium yoelii sporozoites infected mice, the causal prophylactic effects of M8506 at 5, 10 and 20 mg(base)/kg were 56.7%, 87.2% and 100%, respectively, comparable to those of primaquine (54.4%, 90.8% and 100%). In P. cynomolgi sporozoites infected rhesus monkeys 4 dosage regimens of the two agents were compared for radical curative effect. On the first day of treatment pyronaridine phosphate 10 mg(base)/kg twice a day were intramuscularly injected to eliminate erythrocytic stages of P. cynomolgi. At the dosage of 3.0 mg(base)/kg/day x 3, both M8506 and primaquine radically cured the monkeys. At 0.75 mg/kg/day x 3, 12 of 13 (92.3%) monkeys cured by M8506, 5 of 9 (55.6%) cured by primaquine. At 1.5 and 0.375 mg/kg/day x 3, the radical curative effects of M8506 were also better than those of primaquine. Since the toxicity of M8506 was significantly milder in mice, rats and dogs than that of primaquine, M8506 has potential as a tissue schizontocide.
Shao
B R
BR
Institute of Parasitic Diseases, Chinese Academy of Preventive Medicine, WHO Collaborating Centre for Malaria, Shanghai.
Ye
X Y
XY
D000634:Aminoquinolines / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D008253:Macaca mulatta; D008288:Malaria / Q000469:parasitology; D051379:Mice; D016789:Plasmodium cynomolgi / Q000187:drug effects*; D010967:Plasmodium yoelii / Q000187:drug effects*; D011319:Primaquine / Q000008:administration & dosage / Q000494:pharmacology / Q000031:analogs & derivatives; D014018:Tissue Distribution / Q000187:drug effects
D000634:Aminoquinolines; D000962:Antimalarials; C069677:M 8506; D011319:Primaquine